Does Medicare cover ketamine infusions for mental health conditions?
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
Ketamine-Derived Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
Boing Boing on MSN6h
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with it
On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
FDA approves standalone use of J&J's ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used ...
health.wusf.usf.edu2d
FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
What is Spravato, an FDA-approved First Standalone Esketamine-based Nasal Spray Monotherapy for Depression?
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...
CNN2d
FDA approves standalone use of J&J’s ketamine-derived depression treatment
Esketamine, the chemical name for Spravato, is a chemical mirror image of anesthetic ketamine, which is also abused as a recreational party drug and goes by the street nickname “Special K”.
Northcountrypublicradio.org3d
FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved... The U.S. Food and Drug Administration has ...
KPBS3d
FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)
Spravato is made from esketamine, one of two mirror-image molecules found in the anesthetic ketamine. It was approved in 2019 for use in adults with major depressive disorder who did not respond ...